Old chemo drug shows promise for genetic subtype of prostate cancer
NCT ID NCT03652493
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested the chemotherapy drug carboplatin in 16 men with metastatic castration-resistant prostate cancer that has specific gene changes in the homologous recombination pathway. The goal was to see if carboplatin could shrink tumors or lower PSA levels. The study is completed, and results may help identify which patients could benefit from this treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Carboplatin
What this could lead to
If successful, this could point toward a treatment option for men with a specific genetic type of advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong
This is a small, early-phase trial with only 16 participants, so results may not apply to everyone. Carboplatin can cause side effects like low blood counts and fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre François Baclesse
Caen, 14076, France
-
Centre Oscar Lambret
Lille, 59000, France
-
Chu Rouen
Rouen, 76000, France
-
Institut Gustave ROUSSy IGR
Villejuif, France